190 related articles for article (PubMed ID: 30349211)
1. High bone turnover status as a risk factor in symptomatic hypocalcemia following denosumab treatment in a male patient with osteoporosis.
Ishikawa K; Nagai T; Tsuchiya K; Oshita Y; Kuroda T; Ito H; Tani S; Dodo Y; Toyone T; Inagaki K
Clin Interv Aging; 2018; 13():1929-1934. PubMed ID: 30349211
[TBL] [Abstract][Full Text] [Related]
2. Impaired residual renal function predicts denosumab-induced serum calcium decrement as well as increment of bone mineral density in non-severe renal insufficiency.
Miyaoka D; Imanishi Y; Ohara M; Hayashi N; Nagata Y; Yamada S; Mori K; Emoto M; Inaba M
Osteoporos Int; 2019 Jan; 30(1):241-249. PubMed ID: 30187112
[TBL] [Abstract][Full Text] [Related]
3. Denosumab-induced hypocalcemia in a patient with hyperthyroidism: a case report.
Park SY; Kim J; Chung HY
Osteoporos Int; 2022 Jan; 33(1):305-308. PubMed ID: 34232341
[TBL] [Abstract][Full Text] [Related]
4. Denosumab-Associated Severe Hypocalcemia in a Patient With Chronic Kidney Disease.
Salim SA; Nair LR; Thomas L; Garla V; Palabindala V; Agarwal M; Fülöp T
Am J Med Sci; 2018 May; 355(5):506-509. PubMed ID: 29753381
[TBL] [Abstract][Full Text] [Related]
5. Prolonged Hypocalcemia Following a Single Dose of Denosumab for Diffuse Bone Metastasis of Gastric Cancer after Total Gastrectomy.
Iizumi S; Shimoi T; Nishikawa T; Kitano A; Sasada S; Shimomura A; Noguchi E; Yunokawa M; Yonemori K; Shimizu C; Fujiwara Y; Tamura K
Intern Med; 2017 Nov; 56(21):2879-2882. PubMed ID: 28943574
[TBL] [Abstract][Full Text] [Related]
6. Severe and prolonged hypocalcemia after a single dose of denosumab for metastatic breast cancer with diffuse bone involvement without prior calcium/vitamin D supplementations.
Uhm SJ; Hall JA; Herrington JD
J Oncol Pharm Pract; 2021 Jul; 27(5):1287-1290. PubMed ID: 33081580
[TBL] [Abstract][Full Text] [Related]
7. A RANKL Wrinkle: Denosumab-Induced Hypocalcemia.
Laskowski LK; Goldfarb DS; Howland MA; Kavcsak K; Lugassy DM; Smith SW
J Med Toxicol; 2016 Sep; 12(3):305-8. PubMed ID: 26987988
[TBL] [Abstract][Full Text] [Related]
8. A case of denosumab-induced hypocalcaemia in a patient with non-metastatic prostate cancer and renal impairment.
Blackley S; Anderson K; Berg J
J R Coll Physicians Edinb; 2015; 45(2):133-5. PubMed ID: 26181529
[TBL] [Abstract][Full Text] [Related]
9. Severe hypocalcemia following denosumab treatment in a patient with secondary osteoporosis associated with primary sclerosing cholangitis.
Yasuda Y; Iwama S; Arima H
Endocr J; 2019 Mar; 66(3):271-275. PubMed ID: 30713246
[TBL] [Abstract][Full Text] [Related]
10. Safety of denosumab in dialysis patients on calcium and vitamin D supplements.
Ullah A; Abdulnabi K; Khalil A; Alexander J; Pai P; Mishra V
Saudi J Kidney Dis Transpl; 2017; 28(1):158-161. PubMed ID: 28098118
[No Abstract] [Full Text] [Related]
11. Risk Analysis of Denosumab-Induced Hypocalcemia in Bone Metastasis Treatment: Renal Dysfunction Is Not a Risk Factor for Its Incidence in a Strict Denosumab Administration Management System with Calcium/Vitamin D Supplementation.
Saito Y; Takekuma Y; Komatsu Y; Sugawara M
Biol Pharm Bull; 2021; 44(12):1819-1823. PubMed ID: 34853264
[TBL] [Abstract][Full Text] [Related]
12. Acute hypocalcaemia following denosumab in heart and lung transplant patients with osteoporosis.
Shrosbree JE; Elder GJ; Eisman JA; Center JR
Intern Med J; 2018 Jun; 48(6):681-687. PubMed ID: 29363863
[TBL] [Abstract][Full Text] [Related]
13. Denosumab-associated hypocalcemia: Does gender play a role?
Diker-Cohen T; Amitai O; Shochat T; Shimon I; Tsvetov G
Maturitas; 2020 Dec; 142():17-23. PubMed ID: 33158483
[TBL] [Abstract][Full Text] [Related]
14. Denosumab-Induced Hypocalcemia and Hyperparathyroidism in de novo Kidney Transplant Recipients.
Cianciolo G; Tondolo F; Barbuto S; Iacovella F; Zavatta G; Altieri P; Grandinetti V; Comai G; Cozzolino M; La Manna G
Am J Nephrol; 2021; 52(8):611-619. PubMed ID: 34518468
[TBL] [Abstract][Full Text] [Related]
15. Activated vitamin D3 formulations can be safely used as concomitant medication for prevention of denosumab-induced hypocalcemia in women with postmenopausal osteoporosis.
Saito S; Sugo Y; Tsuburai T; Kurasawa K; Nakamura T; Yoshikata H; Miyagi E; Sakakibara H
J Obstet Gynaecol Res; 2019 Apr; 45(4):908-914. PubMed ID: 30618176
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of denosumab in osteoporotic hemodialysed patients.
Festuccia F; Jafari MT; Moioli A; Fofi C; Barberi S; Amendola S; Sciacchitano S; Punzo G; Menè P
J Nephrol; 2017 Apr; 30(2):271-279. PubMed ID: 27394428
[TBL] [Abstract][Full Text] [Related]
17. Severe hypocalcemia after denosumab administration in a patient with chronic kidney disease: a case report.
Kouroglou E; Tsiama V; Dionysopoulou S; Gavriiloglou G; Bora M; Belis K; Proikaki S; Savvidis C; Giannou P; Petras D
J Musculoskelet Neuronal Interact; 2023 Jun; 23(2):285-289. PubMed ID: 37259667
[TBL] [Abstract][Full Text] [Related]
18. Denosumab-associated hypocalcaemia: incidence, severity and patient characteristics in a tertiary hospital setting.
Huynh AL; Baker ST; Stewardson AJ; Johnson DF
Pharmacoepidemiol Drug Saf; 2016 Nov; 25(11):1274-1278. PubMed ID: 27255807
[TBL] [Abstract][Full Text] [Related]
19. [Changes of serum calcium and bone turnover markers in maintenance hemodialysis patients treated with denosumab].
Wang Y; Zhu L; Yang B; Gan LY; Zuo L
Zhonghua Yi Xue Za Zhi; 2023 Feb; 103(8):594-597. PubMed ID: 36822871
[TBL] [Abstract][Full Text] [Related]
20. Denosumab-induced hypocalcemia in patients with osteoporosis: can you know who will get low?
Tsvetov G; Amitai O; Shochat T; Shimon I; Akirov A; Diker-Cohen T
Osteoporos Int; 2020 Apr; 31(4):655-665. PubMed ID: 31838550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]